Sugi Predict

Sugi Predict / Compounds / SCHEMBL1767596

SCHEMBL1767596

SCHEMBL1767596

CC(=O)c1ccccc1N[C@@H](C)C(=O)O

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ AKR1C3 P42330 2/20 0.46
▸ AKR1C2 P52895 2/20 0.46
▸ LMNA P02545 4/20 0.44
▸ SMN1; SMN2 Q16637 1/20 0.44
▸ PDK1 Q15118 1/20 0.43
▸ PDK2 Q15119 1/20 0.43
▸ PDK3 Q15120 1/20 0.43
▸ PDK4 Q16654 1/20 0.43
▸ POLB P06746 1/20 0.42
▸ CYP2C19 P33261 1/20 0.42
▸ CNR2 P34972 1/20 0.41
▸ AKR1B10 O60218 1/20 0.41
▸ AKR1B1 P15121 1/20 0.41
▸ AKR1C4 P17516 1/20 0.41
▸ AKR1C1 Q04828 1/20 0.41
▸ KDM4E B2RXH2 2/20 0.40
▸ CCKAR P32238 1/20 0.40
▸ ALDH1A1 P00352 2/20 0.40
▸ TDP1 Q9NUW8 1/20 0.40
▸ MEN1 O00255 2/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1061793 1.00 AKR1C3 (0.46) AKR1C3AKR1C2LMNASMN1; SMN2PDK1
SCHEMBL5512525 0.87 KMT2A (0.51) AKR1C3AKR1C2LMNASMN1; SMN2CYP2C19
SCHEMBL27274109 0.84 KDM4E (0.47) SMN1; SMN2POLBKDM4EALDH1A1HPGD
SCHEMBL31552440 0.83 AKR1C3 (0.46) AKR1C3AKR1C2LMNAPDK1PDK2
SCHEMBL12411070 0.83 AKR1C3 (0.46) AKR1C3AKR1C2LMNAPDK1PDK2
SCHEMBL10864406 0.83 KMT2A (0.55) AKR1C3ALDH1A1KMT2A
SCHEMBL9488355 0.83 ALDH1A1 (0.52) AKR1C3AKR1C2LMNASMN1; SMN2PDK1
SCHEMBL8153691 0.83 ALDH1A1 (0.52) AKR1C3AKR1C2LMNASMN1; SMN2PDK1
SCHEMBL11195590 0.83 ALDH1A1 (0.46) AKR1C3AKR1C2LMNASMN1; SMN2PDK1
SCHEMBL2588918 0.83 KMT2A (0.55) AKR1C3ALDH1A1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20190010123-A1 PROCESS FOR THE PREPARATION OF APREMILAST ALIVUS LIFE SCIENCES LIMITED (IN) 2019-01-10 — — US claimed
EP-3341359-A1 PROCESS FOR PREPARATION OF APREMILAST Glenmark Pharmaceuticals Limited (IN) 2018-07-04 — — EP claimed
US-20180162833-A1 PROCESS FOR THE PREPARATION OF EFINACONAZOLE GLENMARK LIFE SCIENCES LIMITED (IN) 2018-06-14 — — US claimed
WO-2017033116-A1 PROCESS FOR PREPARATION OF APREMILAST GLENMARK PHARMACEUTICALS LIMITED (IN) 2017-03-02 — — WO claimed
WO-2016193917-A1 PROCESS FOR THE PREPARATION OF EFINACONAZOLE GLENMARK PHARMACEUTICALS LIMITED (IN) 2016-12-08 — — WO claimed
EP-3341359-B1 PROCESS FOR PREPARATION OF APREMILAST GLENMARK LIFE SCIENCES LTD (IN) 2022-03-23 — — EP disclosed
US-20190010123-A1 PROCESS FOR THE PREPARATION OF APREMILAST ALIVUS LIFE SCIENCES LIMITED (IN) 2019-01-10 — — US disclosed
US-10125115-B2 Process for the preparation of efinaconazole GLENMARK PHARMACEUTICALS LIMITED (IN) 2018-11-13 — — US disclosed
US-20180162833-A1 PROCESS FOR THE PREPARATION OF EFINACONAZOLE GLENMARK LIFE SCIENCES LIMITED (IN) 2018-06-14 — — US disclosed
US-9701993-B2 Artificial translation/synthesis system THE UNIVERSITY OF TOKYO (JP) 2017-07-11 — — US disclosed
US-9175061-B2 Protein conjugates and methods for their preparation NOVO NORDISK HEALTH CARE AG (CH) 2015-11-03 — — US disclosed
US-20130217599-A1 NOVEL ARTIFICIAL TRANSLATION/SYNTHESIS SYSTEM THE UNIVERSITY OF TOKYO (JP) 2013-08-22 — — US disclosed
EP-2610348-A1 NOVEL ARTIFICIAL TRANSLATION/SYNTHESIS SYSTEM The University of Tokyo (JP) 2013-07-03 — — EP disclosed
US-20110263501-A1 Growth Hormone Conjugate with Increased Stability Nono Nordisk Health Care AG (CH) 2011-10-27 — — US disclosed
US-20110144017-A1 Protein conjugates and methods for their preparation NOVO NORDISK HEALTH CARE AG (CH) 2011-06-16 — — US disclosed
EP-2324056-A1 GROWTH HORMONE CONJUGATE WITH INCREASED STABILITY Novo Nordisk Health Care AG (CH) 2011-05-25 — — EP disclosed
WO-2010029107-A1 GROWTH HORMONE CONJUGATE WITH INCREASED STABILITY NOVO NORDISK HEALTH CARE AG (CH) 2010-03-18 — — WO disclosed
EP-2040757-A2 NEW PROTEIN CONJUGATES AND METHODS FOR THEIR PREPARATION Novo Nordisk Health Care AG (CH) 2009-04-01 — — EP disclosed
WO-2008003750-A2 NEW PROTEIN CONJUGATES AND METHODS FOR THEIR PREPARATION NOVO NORDISK HEALTH CARE AG (DK) 2008-01-10 — — WO disclosed
EP-0849274-A1 Bissteroidal compounds and their use for the preparation of chiral complexes SCHERING AKTIENGESELLSCHAFT (DE) 1998-06-24 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180162833-A1 PROCESS FOR THE PREPARATION OF EFINACONAZOLE CYP3A43, CYP3A5, CYP51A1 AKR1C3 86/4885AKR1C2 131/4885LMNA 2783/4885
US-10125115-B2 Process for the preparation of efinaconazole CYP3A43, CYP3A5, CYP51A1 AKR1C3 86/4885AKR1C2 131/4885LMNA 2783/4885
US-20110263501-A1 Growth Hormone Conjugate with Increased Stability GHRHR, GHITM, GHSR AKR1C3 1555/4885AKR1C2 1282/4885LMNA 4242/4885
US-20190010123-A1 PROCESS FOR THE PREPARATION OF APREMILAST APRT, QDPR, DPYD AKR1C3 131/4885AKR1C2 195/4885LMNA 1514/4885
US-20110144017-A1 Protein conjugates and methods for their preparation PTMS, DNPEP, ANPEP AKR1C3 2147/4885AKR1C2 2196/4885LMNA 2302/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.